Candriam S.C.A. Mirum Pharmaceuticals, Inc. Call Options Transaction History
Candriam S.C.A.
- $17.1 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding MIRM
# of Institutions
188Shares Held
53.9MCall Options Held
177KPut Options Held
80.3K-
Frazier Life Sciences Management, L.P. Menlo Park, CA6.57MShares$304 Million13.79% of portfolio
-
Janus Henderson Group PLC London, X04.48MShares$207 Million0.09% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.45MShares$159 Million2.37% of portfolio
-
Black Rock Inc. New York, NY3.24MShares$150 Million0.0% of portfolio
-
Bvf Inc San Francisco, CA3.08MShares$142 Million3.81% of portfolio
About Mirum Pharmaceuticals, Inc.
- Ticker MIRM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,751,700
- Market Cap $1.7B
- Description
- Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...